CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib (NoLEEta)
We are pleased to inform you that the Canadian Cancer Trials Group (CCTG) is organizing our next Clinical Research Associate (CRA) Lunch and Learn training program, to be held on Wednesday, May 13th, 2026, at 12 pm ET on the topic: NCTN Clinical Trial Support Unit (CTSU) OPEN System and upcoming changes
Congratulations to Dr. Ali Hosni Abdalaty from Princess Margaret Cancer Centre (UHN) for his Ralph Meyer Phase III Program Young Investigator Award received at the CCTG Spring Meeting.
Congratulations to the PR22 Team Centre hospitalier universitaire de Sherbrooke who were recognized with the Phase III Team Award for Intergroup-Led Trials at the CCTG Spring Meeting. This award is presented to trial teams from member centres for performance in trial accrual, local activation timelines, compliance metrics and team performance.
Congratulations to Dr. Anna Spreafico from Princess Margaret Cancer Centre (UHN) who received the Elizabeth Eisenhauer Early Drug Development Young Investigator Award at the CCTG Spring Meeting.
CCTG IND243: A Phase II Study of RP-6306 in Patients with Advanced Cancer has been centrally activated.
This study is being done to answer the following questions:
To ensure the security and safety of National Cancer Institute (NCI) systems, subjects, research staff, and all associated sensitive information, NCI introduced an identity verification system to access to the Cancer Therapy Evaluation Program (CTEP) and the Cancer Trails Support Unit (CTSU) websites in accordance with the Federal Information Security Management Act(FISMA) in July 2022. This new process uses ID.me, and requires completion of Identity Proofing (IP) and establishment of a Multi Factor Authentication (MFA) method as part of the registration process.
Request an invitation portal: closes April 17th
Online Registration: closes April 19th
On-site Registration: Beat the Friday morning line-up and register on Thursday!!
